

Peter Gottlieb

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10942957/publications.pdf>

Version: 2024-02-01

16
papers

1,605
citations

840776

11
h-index

996975

15
g-index

16
all docs

16
docs citations

16
times ranked

1772
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Anti-interleukin-21 antibody and liraglutide for the preservation of β -cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 212-224. | 11.4 | 85 |
| 2 | Proinsulin:C-peptide ratio trajectories over time in relatives at increased risk of progression to type 1 diabetes. <i>Journal of Translational Autoimmunity</i> , 2021, 4, 100089. | 4.0 | 3 |
| 3 | Unmethylated Insulin as an Adjunctive Marker of Beta Cell Death and Progression to Type 1 Diabetes in Participants at Risk for Diabetes. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3857. | 4.1 | 9 |
| 4 | Single-Cell Analysis of CD4 T Cells in Type 1 Diabetes: From Mouse to Man, How to Perform Mechanistic Studies. <i>Diabetes</i> , 2019, 68, 1886-1891. | 0.6 | 6 |
| 5 | Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data. <i>Diabetes</i> , 2019, 68, 1267-1276. | 0.6 | 80 |
| 6 | Combinatorial detection of autoreactive CD8+ T cells with HLA-A2 multimers: a multi-centre study by the Immunology of Diabetes Society T Cell Workshop. <i>Diabetologia</i> , 2018, 61, 658-670. | 6.3 | 22 |
| 7 | Abnormal T Cell Frequencies, Including Cytomegalovirus-Associated Expansions, Distinguish Seroconverted Subjects at Risk for Type 1 Diabetes. <i>Frontiers in Immunology</i> , 2018, 9, 2332. | 4.8 | 12 |
| 8 | ECL-IAA and ECL-GADA Can Identify High-Risk Single Autoantibody-Positive Relatives in the TrialNet Pathway to Prevention Study. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 410-414. | 4.4 | 25 |
| 9 | Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?. <i>Diabetes Care</i> , 2016, 39, 1738-1744. | 8.6 | 19 |
| 10 | Immune Therapy and β -Cell Death in Type 1 Diabetes. <i>Diabetes</i> , 2013, 62, 1676-1680. | 0.6 | 73 |
| 11 | Validity and Reproducibility of Measurement of Islet Autoreactivity by T-Cell Assays in Subjects With Early Type 1 Diabetes. <i>Diabetes</i> , 2009, 58, 2588-2595. | 0.6 | 92 |
| 12 | Immunotherapy for the Prevention and Treatment of Type 1 Diabetes. <i>Diabetes Care</i> , 2009, 32, 1769-1782. | 8.6 | 71 |
| 13 | Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years. <i>Clinical Immunology</i> , 2009, 132, 166-173. | 3.2 | 184 |
| 14 | Expansion of a unique T cell subset Th40 describes a commonality in type 1 diabetes and MS. <i>FASEB Journal</i> , 2008, 22, 667-26. | 0.5 | 0 |
| 15 | The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 17040-17045. | 7.1 | 843 |
| 16 | Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells. <i>Journal of Autoimmunity</i> , 2003, 21, 365-376. | 6.5 | 81 |